Results 71 to 80 of about 311,459 (229)

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, Bitao Bu   +10 more
wiley   +1 more source

Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica

Arquivos de Neuro-Psiquiatria, 2013
Tonic spasms have been most commonly associated with multiple sclerosis. To date, few reports of series of patients with neuromyelitis optica and tonic spasms have been published.
Luz Abaroa, Sergio A. Rodríguez-Quiroga, Luciana Melamud, Tomoko Arakaki, Nelida S. Garretto, Andres M. Villa   +5 more
doaj   +1 more source

Breast cancer-associated paraneoplastic neuromyelitis optica with cervical cord compression and spondylosis requiring laminectomy: A case report

SAGE Open Medical Case Reports, 2023
Neuromyelitis optica, an autoimmune inflammatory disorder affecting the central nervous system, can occur in a paraneoplastic context, although rare.
Bahadar S Srichawla, Shravan Sivakumar, Seyedeh N Cheraghi, Vincent Kipkorir, Maria A Garcia-Dominguez   +4 more
doaj   +1 more source

The Comprehensive Live Cell‐Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a devastating neurological disease that lacks serological biomarkers that can accurately reflect disease activity. We established a live cell‐based assay (LCBA) using serum with endogenous complement to quantify the overall cytotoxicity, offering a novel functional tool for monitoring
Xiaona Xu, Jie Ding, Yupeng Du, Guibao Luo, Jinming Li, Rui Liu, Xiaoyi Xu, Xiao Li, Minshu Li, Wei Jiang, Chunsheng Yang   +10 more
wiley   +1 more source

Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations

, 2017
Jinming Han,1 Meng-ge Yang,1 Jie Zhu,1,2 Tao Jin1 1Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China; 2Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
Jin, T, Zhu, J,, Zhu J, Yang M, Jin T, Han, J, Yang, M-G, Han J   +7 more
core   +1 more source

Neuroprotection in a Novel Mouse Model of Multiple Sclerosis [PDF]

, 2013
Multiple sclerosis is an immune-mediated, demyelinating and neurodegenerative disease that currently lacks any neuroprotective treatments. Innovative neuroprotective trial designs are required to hasten the translational process of drug development.
Coffey, P, Baker, MD, Coffey Pete, Jackson, SJ, Gavin Giovannoni, Baker David, Samuel J. Jackson (468645), Zubair Ahmed (9352), Jackson Samuel J., Zubair Ahmed, Ahmed, Z, Mark D Baker, Pete Coffey (422262), David Baker, Samuel J Jackson, Gavin Giovannoni (125820), Giovannoni Gavin, Munro Peter, Ahmed Zubair, Pete Coffey, David Baker (11642), Peter Munro (479715), Peter Munro, Lidster Katie, Baker Mark D., Baker, D, Lidster, K, Mark D. Baker (146531), Katie Lidster, Munro, P, Katie Lidster (479714), Giovannoni, G   +31 more
core   +1 more source

Neuromyelitis optica - harvinaissairaus, joka on tärkeä erottaa MS-taudista [PDF]

, 2021
Neuromyelitis optica on autoimmuunisairaus, joka alkuperäisen määritelmänsä mukaan kohdistuu pääasiassa näköhermoratoihin ja selkäytimeen. Viime vuosina taudin diagnostiset kriteerit ja oirekirjo ovat kuitenkin laajentuneet ja nimeksi on muotoutunut ...
Tienari, Pentti, Siuko, Mika, Nieminen, Janne   +2 more
core  

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

Arthritis Care &Research, EarlyView.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci, Megan R. W. Barber, Ann E. Clarke, Sindhu R. Johnson, Anselm Mak, Hermine I. Brunner, Murat Inanc, Rosalind Ramsey‐Goldman, Guillermo Ruiz‐Irastorza, Ellen M. Ginzler, John G. Hanly, Alexandra Legge, Cynthia Aranow, Laurent Arnaud, Nathalie Costedoat‐Chalumeau, Dafna D. Gladman, Søren Jacobsen, Michelle Petri, Clovis A. Silva, Évelyne Vinet, Alexandre E. Voskuyl, SDI Revision Literature Review Groups, SDI Revision Delphi Panel, SDI Revision Item Reduction Committee, SDI Revision Clinical Domain Groups, Ian N. Bruce   +25 more
wiley   +1 more source

The borderland of neuromyelitis optica

Practical Neurology, 2009
Neuromyelitis optica (NMO), also known as Devic’s disease, is an emerging clinical and pathological entity originally thought to be a variant of multiple sclerosis. Characterised by episodes of demyelination confined to the optic nerve and spinal cord, the discovery in such patients of antibodies to the aquaporin-4 channel has been largely responsible ...
Matthews, L, Baig, F, Palace, J, Turner, M   +3 more
openaire   +3 more sources

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

Advanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu, Zhou Jing Zhang, Jing Jin, Hai Yuan Xu, Ya Xin Gu, Qian Qian Yang, You Lang Zhou   +6 more
wiley   +1 more source